Dana-Farber Cancer Institute
Boston, MA
Accepting patients
AZTOUND
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
- Has results
Accepting patients
TRX-103
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
- T Cell (Allogeneic)
- Post-Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
IS-free Treg Stem Cell Transplant
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
- Allogeneic Stem Cell Transplant
- Phase 1
- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Phase 1
Accepting patients
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Natural Killer Cells
- Chemotherapy
- Phase 1
Accepting patients
Venetoclax Basket Trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
- Hypomethylating Agents (HMA)
- Antimetabolites
- BCL-2 Inhibitor
- Steroid
- Phase 1
Accepting patients
MORE
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
- White Blood Cell Stimulant
- Hypomethylating Agents (HMA)
- Maintenance
- Phase 2
Accepting patients
LP-118
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
- Bcl/xL Inhibitor
- BCL-2 Inhibitor
- Phase 1
Accepting patients
Safety Study of Cord Blood Units
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
AG-120
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- IDH1 Inhibitor
- Phase 1